Clinical trials: Tenosynovial Giant Cell Tumor, open to volunteers
Tenosynovial Giant Cell Tumor
Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
The primary purpose of this study is to assess the tolerability, pharmacokinetics, and efficacy of pimicotinib in Japanese participants with TGCT
- Trial name
- NCT07499362
- Testing
- Pimicotinib
- Where
- 4 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Tenosynovial Giant Cell Tumor
A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT
To evaluate the efficacy, safety, and pharmacokinetics of DCC-3014 in subjects with Tenosynovial Giant Cell Tumor
- Trial name
- NCT07832747
- Testing
- DCC-3014
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Adipocytic Neoplasm, Liposarcoma
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
The study participant has been diagnosed with non-rhabdomyosarcoma (NRSTS). Primary Objectives Intermediate-Risk To estimate the 3-year event-free survival for intermediate-risk patients treated with ifosfamide, doxorubicin…
- Conditions
- Adipocytic Neoplasm, Liposarcoma, Atypical Fibroxanthoma, Angiomatoid Fibrous Histiocytoma
- Trial name
- NCT06239272
- Testing
- Surgical resection, Proton beam radiation therapy, Pazopanib
- Where
- 7 sites in United States
- Volunteers
- 139 people
- Sponsor
- St. Jude Children's Research Hospital
Tenosynovial Giant Cell Tumor
MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib
The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.
- Trial name
- MOVE (NCT07075471)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor, Diffuse
Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor
Tenosynovial giant cell tumor (TGCT) is a rare neoplasm predominantly occurring in young and middle-aged adults, characterized by high recurrence and high disability rates. Surgery represents the first-line treatment at present.
- Trial name
- NEXPERT (NCT07707882)
- Testing
- Pimicotinib, Tumor resection surgery
- Where
- China
- Volunteers
- 84 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Neoplasms, Tenosynovial Giant Cell Tumor
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021.
- Trial name
- NCT04192344
- Testing
- ABSK021
- Where
- 17 sites in United States, China
- Volunteers
- 276 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Tenosynovial Giant Cell Tumor
Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery
This study evaluates the diagnostic accuracy of Indocyanine Green (ICG) fluorescence imaging in visualizing Tenosynovial Giant Cell Tumor (TGCT) lesions during surgery.
- Trial name
- ICG-TGCT (NCT07315841)
- Testing
- Indocyanine Green
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Jiao Tong University Affiliated Sixth People's Hospital